Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843460 | 0.86 | PRKCZ (0.52) | GCGRLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL30716573 | 0.86 | GCGR (0.58) | GCGRLMNADHODHIKBKBRAB9A | |
| SCHEMBL1751791 | 0.86 | GCGR (0.58) | GCGRLMNADHODHIKBKBRAB9A | |
| SCHEMBL14282780 | 0.86 | GCGR (0.58) | GCGRLMNADHODHIKBKBRAB9A | |
| SCHEMBL6082682 | 0.85 | ADORA2A (0.44) | GCGRLMNADHODHADORA2AADORA1 | |
| SCHEMBL30414624 | 0.85 | GCGR (0.57) | GCGRLMNADHODHIKBKBRAB9A | |
| SCHEMBL1751492 | 0.85 | GCGR (0.57) | GCGRLMNADHODHIKBKBRAB9A | |
| SCHEMBL1752147 | 0.84 | GCGR (0.56) | GCGRLMNADHODHIKBKBRAB9A | |
| SCHEMBL4787798 | 0.83 | GCGR (0.43) | GCGRLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL945897 | 0.82 | GCGR (0.55) | GCGRLMNADHODHIKBKBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784171-B2 | REACTION OF METHYL 2-AMINO-4-(4-FLUOROPHENYL)-6-ISOPROPYL-PYRIMIDINE-5-CARBOXYLATE WITH METHANESULFONYL CHLORIDE IN THE PRESENCE OF STRONG BASE, REACTION OF THE INTERMEDIATE WITH A METHYLATING AGENT IN PRESENCE OF STRONG BASE | ASTRAZENECA (SE) | 2004-08-31 | — | — | US | claimed |
| US-8614320-B2 | Preparation of aminopyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2013-12-24 | — | — | US | disclosed |
| US-20120277432-A1 | Preparation of Aminopyrimidine Compounds | ASTRAZENECA UK LTD. (GB) | 2012-11-01 | — | — | US | disclosed |
| US-8273878-B2 | Process for the preparation of pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2012-09-25 | — | — | US | disclosed |
| US-8222412-B2 | Preparation of aminopyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20110160455-A1 | Preparation of Aminopyrimidine Compounds | ASTRAZENECA UK LTD. (GB) | 2011-06-30 | — | — | US | disclosed |
| US-7816528-B2 | Preparation of aminopyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2010-10-19 | — | — | US | disclosed |
| EP-1873148-B1 | Pharmaceutical compositions containing crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid | ASTRAZENECA AB (SE) | 2009-11-18 | — | — | EP | disclosed |
| EP-1578731-B1 | PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2009-11-11 | — | — | EP | disclosed |
| US-20090264654-A1 | PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| US-20030199695-A1 | Preparation of 4-(4-flourophenyl)-6-alkyl-2-N-alkansulfonyl-N-alkylamino)pyrimidine-5-carboxylic acid ester. | VEITH ULRICH (CH) | 2003-10-23 | — | — | US | disclosed |
| US-6579984-B1 | Economical, industrially feasible | LONZA AG (CH) | 2003-06-17 | — | — | US | disclosed |
| US-20030045718-A1 | Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid | SHIONOGI & CO. LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
| WO-2003006439-A1 | PREPARATION OF AMINOPYRIMIDINE COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2003-01-23 | — | — | WO | disclosed |
| EP-1263739-A1 | CRYSTALLINE SALTS OF 7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL]-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1194414-A1 | PROCESS FOR PREPARING 2-AMINO-4-(4-FLUORPHENYL)-6-ALKYLPYRIMIDINE-5-CARBOXYLATE | Lonza AG (CH) | 2002-04-10 | — | — | EP | disclosed |
| EP-1155015-A1 | PROCESS FOR THE PRODUCTION OF TERT-BUTYL (E)-(6-[2-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL]VINYL](4R,6S)-2,2-DIMETHYL[1,3]DIOXAN-4-YL)ACETATE | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2001060804-A1 | CRYSTALLINE SALTS OF 7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL]-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID | ASTRAZENECA AB (SE) | 2001-08-23 | — | — | WO | disclosed |
| WO-2001004100-A1 | PROCESS FOR PREPARING 2-AMINO-4-(4-FLUORPHENYL)-6-ALKYLPYRIMIDINE-5-CARBOXYLATE | LONZA AG (CH) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000049014-A1 | PROCESS FOR THE PRODUCTION OF TERT-BUTYL (E)-(6-[2- [4-(4-FLUOROPHENYL) -6-ISOPROPYL-2-[ METHYL (METHYLSULFONYL) AMINO] PYRIMIDIN-5-YL] VINYL](4R, 6S)-2,2-DIMETHYL [1,3]DIOXAN-4-YL) ACETATE | ASTRAZENECA AB (SE) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264654-A1 | PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS | DPYD, RIOX2, CCNE1 | GCGR 2600/4885LMNA 2945/4885DHODH 88/4885 |
| US-20030045718-A1 | Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid | EIF5B, SF3B5, NT5C3B | GCGR 1863/4885LMNA 2872/4885DHODH 126/4885 |
| US-20110160455-A1 | Preparation of Aminopyrimidine Compounds | DPYD, UMPS, IDH3B | GCGR 3740/4885LMNA 4126/4885DHODH 192/4885 |
| US-20120277432-A1 | Preparation of Aminopyrimidine Compounds | DPYD, UMPS, IDH3B | GCGR 3740/4885LMNA 4126/4885DHODH 192/4885 |
| US-20030199695-A1 | Preparation of 4-(4-flourophenyl)-6-alkyl-2-N-alkansulfonyl-N-alkylamino)pyrimidine-5-carboxylic acid ester. | PFAS, F7, AFF1 | GCGR 2758/4885LMNA 1641/4885DHODH 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.